Skip to main content

Table 1 CN ADNI subjects included in the longitudinal study

From: Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition

 

ADNI-1

ADNI-GO/2

CN stable ADNI-1 vs. ADNI-GO/2

 

CN stable (n = 120)

CN progressors (n = 35)

p-value

CN stable (n = 163)

CN progressors (n = 8)

p-value

p-value

Progression to

-

29 MCI

-

-

7 MCI

-

 

6 AD

1 AD

Age at baseline (years)

74.9 (72.0-78.5)

77.0 (73.0-79.2)

0.37

72.6 (69.4-77.1)

83.0 (80.4-84.8)

0.0001

0.0001

Gender (% male)

52.5%

57.1%

0.49

50.9%

75.0%

0.28

0.89

Education (years)

16.0 (14.0-18.0)

16.0 (13.0-18.0)

0.52

16.0 (15.0-18.5)

17.0 (13.8-18.5)

0.86

0.060

APOE ϵ4 presence

22.5%

31.4%

0.39

29.5%

12.5%

0.44

0.22

ADAS-Cog

9.33 (6.0-12.3)

10.8 (8.6-13.3)

0.047

9.0 (6.0-11)

15.0 (13.5-16.5)

0.0003

0.31

Memory summary score

0.94 (0.66-1.37)

0.71 (0.44-1.01)

0.006

0.94 (0.55-1.22)

0.22 (0.02-0.42)

0.0004

0.16

Executive summary score

0.66 (0.29-1.22)

0.40 (0.03-0.77)

0.039

0.82 (0.40-1.44)

0.23 [(−0.15)-0.47]

0.004

0.091

aHV1

812.0 (347.3-1244.5)

586.8 (94.5-1322.6)]

0.25

529.8 (9.0-1085.3)

−226.1 [(−419.3)-(6.7)]

0.007

0.015

SPARE-AD

−1.44 [(−2.15)-(−0.99)]

−1.17 [(−1.74)-(−0.68)]

0.053

−1.32 [(−1.61)-(−1.07)]

−0.90 [(−1.04)-(−0.30)]

0.029

0.019

HCI

5.3 (3.3-7.5)

6.0 (3.9-8.7)

0.20

5.5 (3.5-7.7)

7.2 (3.5-13.6)

0.051

0.29

PC-FDG-PET

1.38 (1.29-1.53)

1.29 (1.23-1.43)

0.022

1.45 (1.33-1.51)

1.31 (1.20-1.36)

0.014

0.54

1–42 (pg/ml)

222.0 (163.5-257.0)

210.0 (144.5-235.0)

0.25

207.7 (158.3-237.3)

147.8 (108.2-205.7)

0.083

0.065

T-tau (pg/ml)

60.0 (47.5-80.8)

71.5 (54.3-95.3)

0.13

56.3 (45.6-81.0)

111.5 (93.7-123.4)

0.032

0.53

P-tau181 (pg/ml)

20.0 (16.0-27.5)

22.0 (17.0-31.5)

0.36

30.0 (21.9-43.1)

35.6 (31.0-44.0)

0.25

<0.0001

  1. aHV = adjusted hippocampal volume.
  2. 1Adjusted for intracranial volume.
  3. Median (1st quartile-3rd quartile).